Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07593209

First-in-Human Study of the Radioligand 68Ga- DOTA-EphA2

Sponsor: First Hospital of China Medical University

View on ClinicalTrials.gov

Summary

Purpose Ephrin type-A receptor 2 (EphA2) is a receptor tyrosine kinase overexpressed in various solid tumors and associated with tumor progression, metastasis, and poor prognosis. However, noninvasive imaging tools for assessing EphA2 expression in vivo remain limited. This study aims to develop a novel 68Ga-labeled EphA2-targeting positron emission tomography (PET) tracer for specific imaging of EphA2-positive malignancies.

Official title: Development and Evaluation of 68Ga-DOTA-EphA2: A Novel Imaging Agent Targeting EphA2 for Malignant Tumor

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

OBSERVATIONAL

Enrollment

30

Start Date

2026-05-01

Completion Date

2027-12-31

Last Updated

2026-05-18

Healthy Volunteers

No

Conditions

Interventions

DEVICE

68Ga- DOTA-EphA2 PET/CT Imaging of Malignant Tumor

Study of the Radioligand 68Ga- DOTA-EphA2 for PET/CT Imaging of Malignant Tumor

Locations (1)

PET

Shenyang, Liaoning, China